Cough Assisted Devices Market Summary

• The Cough Assist Devices market is estimated at USD 203 million in 2025 and is projected to reach USD 360 million by 2034. Growth is anchored in the rising prevalence of neuromuscular disorders that impair cough, the expansion of home-based respiratory care, and continued innovation in portable and multifunctional mechanical insufflation-exsufflation devices.
• The global Cough Assist Devices market is growing at a CAGR of 6.6% during the forecast period from 2026 to 2034.
• By product type, the standalone cough assist devices segment dominated the Cough Assist Devices market with a 72% share in 2025.
• By portability, the portable cough assist devices segment dominated the Cough Assist Devices market with a share of 58% in 2025.
• By application, the neuromuscular disorders segment dominated the Cough Assist Devices market with a share of 54% in 2025.
• By end-user, the home care settings segment dominated the Cough Assist Devices market with a share of 47% in 2025.
• North America dominated the global Cough Assist Devices market revenue with a share of 40% in 2025, representing the highest regional market share globally.

Cough assist devices, also known as mechanical insufflation-exsufflation (MI-E) devices, are respiratory therapy systems that help clear secretions from the airways of patients who cannot cough effectively on their own. The device applies a positive pressure to the airway to fully inflate the lungs (insufflation) and then rapidly shifts to negative pressure (exsufflation), simulating a natural cough to mobilize and remove mucus. A complete cough assist solution comprises the MI-E device, which may be standalone or integrated within a multifunction respiratory platform and configured as a stationary or portable unit, along with masks, mouthpieces, circuits, and filters. Cough assist devices are essential for patients with neuromuscular disorders such as amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and spinal muscular atrophy, as well as spinal cord injury and certain chronic respiratory conditions, where impaired cough increases the risk of respiratory infections and hospitalization. Over the past decade, the field has advanced from stationary hospital units toward portable, battery-powered, and oscillation-enhanced devices and integrated ventilation platforms, positioning cough assist devices as an important component of airway clearance across hospital and home care settings worldwide.

Cough Assist Devices Market Key Growth Drivers 

• The rising prevalence of neuromuscular disorders, including amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and spinal muscular atrophy, is a primary driver, as these conditions impair cough and require airway clearance.
• Clinical guidelines for neuromuscular disease respiratory care recommend mechanical insufflation-exsufflation to prevent respiratory complications, supporting adoption.
• The expansion of home-based respiratory care is broadening access to cough assist devices for long-term management outside the hospital.
• The aging population and rising burden of respiratory and chronic conditions are increasing the population requiring airway clearance support.
• Technological advances, including portable, battery-powered, oscillation-enhanced, and multifunctional integrated devices, are improving usability and driving adoption.
• Growing awareness of airway clearance therapy to reduce respiratory infections and hospitalizations in at-risk patients is supporting demand.
• The convergence of rising neuromuscular disease burden, guideline-supported use, home care expansion, and device innovation is expected to sustain steady growth in the global Cough Assist Devices market through 2034.

Key Companies in Cough Assist Devices Market

The competitive landscape is led by the following active manufacturers and solution providers:

• Koninklijke Philips N.V.
• Baxter International Inc. (Hillrom)
• Breas Medical
• ABM Respiratory Care
• Ventec Life Systems (React Health, Inc.)
• Air Liquide Medical Systems
• Dima Italia Srl
• United Hayek Industries, Inc.
• Lowenstein Medical Technology GmbH & Co. KG
• Well Lead Medical Co., Ltd.

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Cough Assist Devices Market Size

The following snapshot summarizes the principal report metrics for the Cough Assist Devices market.

All market values are expressed in USD at the manufacturer revenue level and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Cough Assist Devices Market

Market Drivers

Rising Prevalence of Neuromuscular Disorders

The increasing prevalence of neuromuscular disorders is the foundational driver of cough assist device demand. Conditions such as amyotrophic lateral sclerosis, Duchenne muscular dystrophy, spinal muscular atrophy, and myasthenia gravis progressively weaken the respiratory muscles, impairing the ability to generate an effective cough and clear airway secretions. Ineffective cough leads to mucus retention, recurrent respiratory infections, atelectasis, and respiratory failure, which are leading causes of morbidity and mortality in these patients. Mechanical insufflation-exsufflation directly addresses this deficit by simulating a natural cough to mobilize and remove secretions. As diagnosis of neuromuscular disorders improves and as disease-modifying therapies extend survival, particularly in spinal muscular atrophy and Duchenne muscular dystrophy, the population of patients living longer with chronic respiratory muscle weakness grows, increasing the need for long-term airway clearance. The expanding and longer-surviving neuromuscular patient population creates durable and growing demand for cough assist devices, reinforcing sustained market growth throughout the forecast period.

Guideline-Supported Use in Respiratory Care

Clinical guideline support for mechanical insufflation-exsufflation is a significant driver of adoption. Respiratory care guidelines for neuromuscular disorders, including consensus recommendations for Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and spinal muscular atrophy, recommend cough augmentation and mechanical insufflation-exsufflation as standard components of airway clearance to prevent respiratory complications. Professional societies and care standards emphasize proactive airway clearance and cough assistance once cough effectiveness declines, providing clinicians with a clear rationale for prescribing these devices. This guideline endorsement supports reimbursement and encourages earlier and more consistent use across the disease course. As awareness of these recommendations grows among neurologists, pulmonologists, and respiratory therapists, and as care becomes more standardized, the prescription of cough assist devices increases. The alignment of clinical guidelines with proactive airway clearance is expected to remain an important driver of cough assist device adoption across the forecast period, particularly in specialized neuromuscular and respiratory care programs.

Expansion of Home-Based Respiratory Care

The growth of home-based respiratory care is broadening access to cough assist devices and expanding the market. Patients with chronic neuromuscular disease require long-term, often daily, airway clearance that is increasingly delivered at home rather than in the hospital, supported by portable, easy-to-use devices and home respiratory care services. Home use improves quality of life, reduces hospital visits and infections, and enables consistent airway clearance, aligning with health system efforts to shift care to lower-cost settings. The availability of portable, battery-powered cough assist devices, such as portable mechanical insufflator-exsufflators, facilitates this transition, and home respiratory providers increasingly include cough assist in their offerings. Reimbursement for home respiratory equipment supports adoption. As home-based and remote respiratory care continues to expand and as portable device technology improves, the shift toward home use is enlarging the population served by cough assist devices and is expected to be a leading contributor to market growth across the forecast period.

Aging Population and Rising Respiratory Burden

The aging of the global population and the rising burden of respiratory and chronic conditions are expanding the population requiring airway clearance support. Older adults are more susceptible to respiratory muscle weakness, impaired cough, and conditions that compromise secretion clearance, and the growing prevalence of chronic respiratory diseases increases the number of patients who may benefit from cough assistance. Patients recovering from prolonged mechanical ventilation, spinal cord injury, and certain chronic respiratory conditions also require airway clearance support. The heightened awareness of respiratory care following global respiratory health events has reinforced the importance of secretion management and airway clearance. As the population ages and the burden of respiratory compromise rises, the pool of patients who may benefit from cough assist devices grows, particularly in hospital and post-acute settings. This demographic and epidemiological shift is expected to sustain demand for cough assist devices across the forecast period.

Technological Advancement in Device Design

Continuous technological innovation is enhancing the usability and appeal of cough assist devices. Advances have produced portable, lightweight, and battery-powered mechanical insufflator-exsufflators that enable therapy at home and on the move, and devices increasingly incorporate oscillation to enhance secretion mobilization, exemplified by systems that combine cough assist with high-frequency oscillation. Multifunctional platforms integrate cough assist with ventilation and other respiratory therapies, such as devices that consolidate multiple functions into a single unit, reducing equipment burden for patients requiring multiple modalities. Improvements in pressure control, automated and adaptive settings, data monitoring, and connectivity enhance therapy delivery and adherence. These advances make cough assist more accessible, effective, and suitable for home use, expanding candidacy and improving outcomes. As device technology continues to advance toward portability, integration, and intelligent therapy, ongoing innovation is expected to be a significant driver of cough assist device adoption and competitive differentiation across the forecast period.

Growing Awareness of Airway Clearance and Infection Prevention

Rising awareness of the importance of airway clearance in preventing respiratory infections and hospitalizations is supporting cough assist device demand. Respiratory infections and complications from retained secretions are major causes of hospitalization and mortality in patients with impaired cough, and proactive airway clearance with cough assist can reduce these events, improving outcomes and lowering costs. Growing recognition among clinicians, caregivers, and patients of the value of secretion management is encouraging earlier and more consistent use of cough assist devices. Patient advocacy organizations for neuromuscular diseases promote respiratory care awareness, and the demonstrated ability of cough assist to reduce infections strengthens its clinical and economic case. As health systems focus on reducing avoidable hospitalizations and as awareness of proactive airway clearance grows, demand for cough assist devices is expected to increase, contributing to market growth across the forecast period, particularly in home and community care settings.

Market Restraints

Despite steady demand, the Cough Assist Devices market faces material constraints. The market is a relatively small and specialized niche focused on impaired-cough populations, which limits its overall size and the scale of investment it attracts. The cost of devices and the variability of reimbursement across geographies and payers can restrict access, particularly for home use and in cost-sensitive and emerging markets, and coverage for cough assist devices is not uniform. Limited awareness of mechanical insufflation-exsufflation among some clinicians and caregivers, especially outside specialized neuromuscular and respiratory centers, constrains adoption, and effective use requires training and appropriate patient selection and settings. Competition from alternative airway clearance techniques, including manual assisted cough, high-frequency chest wall oscillation, and manual physiotherapy, can substitute for or complement cough assist in some patients. Product quality and safety actions in the broader respiratory device sector, including recalls affecting major manufacturers, can disrupt supply and confidence. The need for prescription and clinical oversight adds complexity to access. Regulatory requirements under frameworks such as the European Medical Device Regulation raise evidence and compliance burdens and lengthen time to market. Finally, uneven access to respiratory specialists and home care infrastructure in emerging markets restrains the pace of adoption across parts of the sector.

Cough Assist Devices Market Segment Analysis

The Cough Assist Devices Market is segmented by Product Type (Standalone Cough Assist Devices, Multifunctional and Integrated Devices), Portability (Portable Cough Assist Devices, Stationary Cough Assist Devices), Application (Neuromuscular Disorders, Spinal Cord Injury, Chronic Respiratory Conditions, Others), End-User (Home Care Settings, Hospitals, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Product Type

Dominant Subsegment: Standalone Cough Assist Devices. 

The standalone cough assist devices segment accounted for 72% of the Cough Assist Devices market in 2025. Standalone mechanical insufflation-exsufflation devices dominate because they are the established, purpose-built solution for cough augmentation and are widely used across hospital and home settings, offering dedicated, optimized cough assist therapy. These devices, such as the Philips CoughAssist E70 and T70 and comparable systems from Hillrom, Breas, and Dima Italia, are the standard prescription for airway clearance in neuromuscular disease and are familiar to clinicians and respiratory therapists. Their focused functionality, established clinical evidence, and broad availability underpin their leading share. Multifunctional and integrated devices, which combine cough assist with ventilation and other respiratory therapies in a single platform, exemplified by systems that consolidate multiple functions, represent a growing segment valued for reducing equipment burden in patients requiring multiple modalities, and they are gaining traction particularly in complex and home ventilation cases. Nonetheless, the established clinical role, dedicated performance, and broad adoption of standalone cough assist devices secure the segment's leadership across the forecast period, while integrated platforms grow among patients needing combined respiratory support.

By Portability

Dominant Subsegment: Portable Cough Assist Devices. 

The portable cough assist devices segment accounted for 58% of the Cough Assist Devices market in 2025. Portable, lightweight, and battery-powered cough assist devices dominate because they enable therapy at home and on the move, aligning with the strong shift of neuromuscular and chronic respiratory care to home settings where patients require long-term, often daily, airway clearance. Portability supports patient mobility, travel, and consistent therapy outside the hospital, improving adherence and quality of life, and manufacturers have prioritized portable designs, including battery-equipped mechanical insufflator-exsufflators such as the Philips CoughAssist T70. The growth of home-based respiratory care and the preference for devices that patients and caregivers can use independently reinforce demand for portable units. Stationary cough assist devices remain important in hospital, intensive care, and institutional settings, where mains-powered units support higher throughput and acute care, and represent a substantial segment. Nonetheless, the shift to home care, patient mobility needs, and continued improvement in portable device technology secure the leadership of portable cough assist devices across the forecast period.

By Application

Dominant Subsegment: Neuromuscular Disorders. 

The neuromuscular disorders segment accounted for 54% of the Cough Assist Devices market in 2025. Neuromuscular disorders dominate because they are the principal indication for cough assist therapy, as conditions such as amyotrophic lateral sclerosis, Duchenne muscular dystrophy, spinal muscular atrophy, and myasthenia gravis progressively weaken respiratory muscles and impair cough, creating a direct and sustained need for mechanical insufflation-exsufflation. Clinical guidelines for these conditions recommend cough augmentation to prevent respiratory infections and complications, entrenching cough assist as a standard of care. The extension of survival through disease-modifying therapies in spinal muscular atrophy and Duchenne muscular dystrophy is increasing the population living long-term with respiratory muscle weakness and requiring ongoing airway clearance. Spinal cord injury represents an important application where impaired cough requires assistance, and chronic respiratory conditions and post-ventilation recovery add further demand. Others, including certain acute and post-surgical situations, contribute additional use. Nonetheless, the central role of cough assist in neuromuscular disease, guideline support, and the growing longer-surviving patient population secure the segment's leadership across the forecast period.

By End-User

Dominant Subsegment: Home Care Settings. 

The home care settings segment accounted for 47% of the Cough Assist Devices market in 2025. Home care settings dominate because patients with chronic neuromuscular disease and impaired cough require long-term, often daily, airway clearance that is delivered predominantly at home over months and years, driving sustained device use and the largest share of long-term demand. The shift of respiratory care to the home, supported by portable, easy-to-use devices and home respiratory care services, has made home the primary setting for ongoing cough assist therapy, improving quality of life and reducing hospital visits and infections. Reimbursement for home respiratory equipment supports this setting. Hospitals represent a large and essential end user, providing acute airway clearance in intensive care, respiratory therapy, and post-surgical settings and often initiating therapy and training before discharge to home, and they anchor institutional purchasing. Other settings, including long-term care and rehabilitation facilities, add further demand. Nonetheless, the long-term, daily nature of airway clearance in chronic neuromuscular disease and the shift to home care secure the leadership of home care settings across the forecast period, with hospitals remaining central to acute care and therapy initiation.

Cough Assist Devices Market Region Analysis

Dominant Region: North America

North America accounted for 40% of the global Cough Assist Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high awareness and diagnosis of neuromuscular disorders, advanced respiratory care infrastructure, and strong adoption of home-based airway clearance. The United States leads on the strength of established neuromuscular and respiratory care programs, favorable reimbursement for cough assist devices and home respiratory equipment, and the presence of leading manufacturers. Disease awareness is high, with active patient advocacy for amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and spinal muscular atrophy, and clinical guidelines supporting mechanical insufflation-exsufflation are widely followed. The regulatory environment is well defined, with the Food and Drug Administration providing established pathways for cough assist devices, and reimbursement through durable medical equipment benefits supports home use. A concentration of leading manufacturers and a mature home respiratory care sector further reinforce demand. This combination of awareness, infrastructure, reimbursement, and manufacturer presence reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Cough Assist Devices market. The region's elevated CAGR is driven by large populations, improving diagnosis and awareness of neuromuscular disorders, and rapidly expanding respiratory and home care infrastructure across China, Japan, India, South Korea, and Australia. Growing healthcare investment, rising awareness of airway clearance therapy, and improving access to respiratory specialists are accelerating adoption of cough assist devices. The expansion of home-based respiratory care and the increasing availability of disease-modifying therapies that extend survival in neuromuscular disease are enlarging the population requiring long-term airway clearance. Both global manufacturers and regional providers are expanding their presence with cough assist devices and cost-effective options tailored to local requirements, and improving reimbursement and healthcare access are broadening adoption beyond major urban centers. Government initiatives to strengthen respiratory and rare disease care further support growth. The combination of large patient populations, improving diagnosis, and expanding home care positions Asia-Pacific as the highest-growth region over the forecast period.

Regional Commentary

North America

North America accounted for 40% of the global Cough Assist Devices market revenue in 2025. The United States dominates the region on the strength of high neuromuscular disease awareness, favorable reimbursement for home respiratory equipment, established respiratory care programs, and the presence of leading manufacturers, while Canada advances through public healthcare respiratory programs and Mexico expands respiratory care within its growing healthcare sector.

Europe

Europe represents the second-largest regional market, led by Germany, France, and the United Kingdom. Growth is supported by strong neuromuscular and respiratory care systems, guideline-driven use of mechanical insufflation-exsufflation, and the presence of manufacturers such as Breas, Dima Italia, Air Liquide, and Lowenstein Medical, while the European Medical Device Regulation shapes requirements for cough assist devices.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by large populations, improving neuromuscular disease diagnosis, and expanding respiratory and home care infrastructure across China, Japan, India, South Korea, and Australia. Growing awareness of airway clearance and expanding home respiratory care are broadening adoption of cough assist devices.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Improving diagnosis of neuromuscular disorders, gradual development of respiratory and home care infrastructure, and increasing availability of cough assist devices are expanding access, while investment in respiratory care capacity supports the broader adoption of cough assist devices.

Cough Assist Devices Market Competitive Landscape

The Cough Assist Devices market is classified as Consolidated. A small group of respiratory device manufacturers controls the majority of revenue, led by Koninklijke Philips, whose CoughAssist devices are a market benchmark, and Baxter through Hillrom, followed by specialized respiratory companies including Breas Medical, ABM Respiratory Care, Ventec Life Systems, Air Liquide Medical Systems, and Dima Italia, with additional regional and emerging players. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Consolidated, with revenue concentrated among a few respiratory device leaders and a specialized field of cough assist and airway clearance providers.
• Leading players: Koninklijke Philips and Baxter (Hillrom) anchor the market, with Breas Medical, ABM Respiratory Care, Ventec Life Systems, and Air Liquide as key specialized providers.
• Geographic reach: Leaders operate global commercial and home respiratory care networks, with strong positions across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players offer standalone and portable cough assist devices and, increasingly, oscillation-enhanced and integrated respiratory platforms.
• Pipeline strength: Active development in portable, battery-powered, oscillation-enhanced, and multifunctional integrated cough assist and ventilation devices.
• Strategic partnerships: Collaborations with home respiratory care providers and distributors extend reach into home and community settings.
• M&A activity: Consolidation continues across respiratory devices, with integration of ventilation and airway clearance capabilities.
• Manufacturing capabilities: Manufacturing of reliable mechanical insufflation-exsufflation devices and accessories is a competitive factor supporting recurring consumable revenue.
• Innovation focus: Portability, oscillation-enhanced secretion clearance, integration with ventilation, and connectivity and adherence monitoring for home use.

Cough Assist Devices Market Recent Developmental Activities

In 2023 and 2024, ABM Respiratory Care advanced its BiWaze Cough system, which combines mechanical insufflation-exsufflation with oscillation for airway clearance. Strategic significance: Introduces oscillation-enhanced cough assist and differentiates ABM in the airway clearance segment, expanding therapeutic options.

In 2023 and 2024, Koninklijke Philips N.V. continued to offer its CoughAssist E70 and portable CoughAssist T70 mechanical insufflator-exsufflators, the market benchmark devices. Strategic significance: Sustains Philips's leadership in dedicated cough assist therapy across hospital and home settings.

In 2023 and 2024, Ventec Life Systems, part of React Health, advanced its multifunction respiratory platform integrating cough assist with ventilation and other therapies. Strategic significance: Reduces equipment burden for complex patients and advances integrated respiratory care.

In 2023 and 2024, Breas Medical advanced its Nippy Clearway mechanical insufflation-exsufflation devices for airway clearance. Strategic significance: Strengthens Breas's position in dedicated cough assist and supports home and hospital use.

In 2023 and 2024, Baxter, through Hillrom, advanced its airway clearance and cough assist portfolio for respiratory care. Strategic significance: Maintains a strong position in airway clearance and respiratory care across care settings.

In 2023 and 2024, Dima Italia Srl and Air Liquide Medical Systems advanced their mechanical insufflation-exsufflation devices for the European and international markets. Strategic significance: Broadens the availability of cough assist devices and supports competition in Europe.

In 2023 and 2024, manufacturers expanded portable and battery-powered cough assist designs to support the shift to home-based respiratory care. Strategic significance: Enables therapy outside the hospital and supports the growth of home care use.

In 2023 and 2024, disease-modifying therapies for spinal muscular atrophy and Duchenne muscular dystrophy extended patient survival, increasing the long-term need for airway clearance. Strategic significance: Enlarges the population requiring cough assist and supports sustained demand.

In 2023 and 2024, clinical guidelines and consensus statements for neuromuscular respiratory care continued to endorse mechanical insufflation-exsufflation for cough augmentation. Strategic significance: Reinforces the standard-of-care role of cough assist and supports reimbursement and adoption.

In 2023 and 2024, quality and safety actions in the broader respiratory device sector, including recalls affecting major manufacturers, influenced supply and purchasing decisions. Strategic significance: Affects competitive dynamics and creates opportunities for alternative providers.

In 2024 and 2025, manufacturers expanded connectivity and adherence-monitoring features in cough assist and respiratory devices for home management. Strategic significance: Supports remote monitoring and adherence, aligning with home-based respiratory care trends.

In 2024 and 2025, the transition to the European Medical Device Regulation continued to shape cough assist device compliance and evidence requirements. Strategic significance: Raises clinical evidence standards and favors established manufacturers with resources to comply.

Cough Assist Devices Market Segmentation

Cough Assist Devices Market by Product Type

• Standalone Cough Assist Devices
• Multifunctional and Integrated Devices

Cough Assist Devices Market by Portability

• Portable Cough Assist Devices
• Stationary Cough Assist Devices

Cough Assist Devices Market by Application

• Neuromuscular Disorders
• Spinal Cord Injury
• Chronic Respiratory Conditions
• Others

Cough Assist Devices Market by End-User

• Home Care Settings
• Hospitals
• Others

Cough Assist Devices Market by Geography

• North America Cough Assist Devices Market

• United States Cough Assist Devices Market Size in USD million (2023-2034)
• Canada Cough Assist Devices Market Size in USD million (2023-2034)
• Mexico Cough Assist Devices Market Size in USD million (2023-2034)

• Europe Cough Assist Devices Market

• Germany Cough Assist Devices Market Size in USD million (2023-2034)
• United Kingdom Cough Assist Devices Market Size in USD million (2023-2034)
• France Cough Assist Devices Market Size in USD million (2023-2034)
• Italy Cough Assist Devices Market Size in USD million (2023-2034)
• Spain Cough Assist Devices Market Size in USD million (2023-2034)
• Rest of Europe Cough Assist Devices Market Size in USD million (2023-2034)

• Asia-Pacific Cough Assist Devices Market

• China Cough Assist Devices Market Size in USD million (2023-2034)
• Japan Cough Assist Devices Market Size in USD million (2023-2034)
• India Cough Assist Devices Market Size in USD million (2023-2034)
• Australia Cough Assist Devices Market Size in USD million (2023-2034)
• South Korea Cough Assist Devices Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Cough Assist Devices Market Size in USD million (2023-2034)

• Rest of the World (RoW) Cough Assist Devices Market

• Middle East Cough Assist Devices Market Size in USD million (2023-2034)
• Africa Cough Assist Devices Market Size in USD million (2023-2034)
• South America Cough Assist Devices Market Size in USD million (2023-2034)

Cough Assist Devices Market Recent Industry Trends and Milestones (2023-2026)

Cough Assist Devices Market Startup Funding and Investment Trends

Investment in the cough assist and airway clearance ecosystem has concentrated on oscillation-enhanced and integrated devices and novel cough augmentation technologies. The following companies illustrate recent activity and technology focus.

ABM Respiratory Care is scaling its BiWaze Cough system, which combines mechanical insufflation-exsufflation with oscillation to enhance airway clearance, while Rehabtronics advances electrical stimulation-assisted cough technology for patients with impaired cough. Additional activity continues around oscillation-enhanced and integrated devices, portable home-use systems, and novel cough augmentation approaches, reflecting conviction that improved secretion clearance, portability, and integration are the next sources of competitive advantage. Collectively, these efforts signal continued investment in improving airway clearance outcomes, expanding home-based use, and broadening the range of cough assist and augmentation options for patients with impaired cough.

Key Takeaways from the Cough Assist Devices Market Report Study

• Market size analysis for the current cough assist devices market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.
• Key companies dominating the global cough assist devices market.
• Various opportunities available for competitors in the cough assist devices market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current cough assist devices market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for cough assist devices market growth in the future?

Target audience who can benefit from this cough assist devices market report study.

• Cough Assist Devices product providers
• Research organizations and consulting companies
• Cough Assist Devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in cough assist devices
• Various end-users who want to know more about the cough assist devices market and the latest technological developments in the cough assist devices market.